Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461-1926, USA.
Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461-1926, USA.
Cell Chem Biol. 2016 May 19;23(5):579-586. doi: 10.1016/j.chembiol.2016.04.009.
In humans, the cytosolic sulfotransferases (SULTs) catalyze regiospecific transfer of the sulfuryl moiety (-SO3) from 3'-phosphoadenosine 5'-phosphosulfate to thousands of metabolites, including numerous signaling small molecules, and thus regulates their activities and half-lives. Imbalances in the in vivo set points of these reactions leads to disease. Here, with the goal of controlling sulfonation in vivo, molecular ligand-recognition principles in the SULT and nuclear receptor families are integrated in creating a strategy that can prevent sulfonation of a compound without significantly altering its receptor affinity, or inhibiting SULTS. The strategy is validated by using it to control the sulfonation and estrogen receptor (ER) activating activity of raloxifene (a US Food and Drug Administration-approved selective estrogen receptor modulator) and its derivatives. Preventing sulfonation is shown to enhance ER-activation efficacy 10(4)-fold in studies using Ishikawa cells. The strategy offers the opportunity to control sulfuryl transfer on a compound-by-compound basis, to enhance the efficacy of sulfonated drugs, and to explore the biology of sulfuryl transfer with unprecedented precision.
在人类中,胞质溶胶磺基转移酶(SULTs)催化将硫酸基部分(-SO3)从 3'-磷酸腺苷 5'-磷酸硫酸转移到数千种代谢物,包括许多信号小分子,从而调节它们的活性和半衰期。这些反应的体内平衡点失衡会导致疾病。在这里,我们的目标是控制体内的磺化作用,整合 SULT 和核受体家族中的分子配体识别原理,创建一种可以防止化合物磺化而不会显著改变其受体亲和力或抑制 SULT 的策略。该策略通过使用它来控制雷洛昔芬(一种美国食品和药物管理局批准的选择性雌激素受体调节剂)及其衍生物的磺化和雌激素受体(ER)激活活性得到验证。研究表明,在使用 Ishikawa 细胞的研究中,该策略可将 ER 激活效力提高 10(4)倍。该策略为在化合物基础上控制硫酸基转移提供了机会,可增强磺化药物的疗效,并以前所未有的精度探索硫酸基转移的生物学。